Kairos Pharma extended its equity financing arrangement with Helena Global Investment Opportunities through Dec. 31, 2028, while changing how the purchase price is calculated. The amendments keep open a source of potential funding through the sale of company shares.
Separately, Kairos announced that its president and chief scientific officer, Neil Bhowmick, would present interim efficacy data from ongoing trials of ENV-105 (carotuximab) at a cancer research conference in Houston on Nov. 3. The announcement does not provide the clinical data or describe the results.
Key details
-
The equity line was extended by one year. Kairos and Helena amended their purchase agreement on Oct. 29 to extend the period in which Kairos can use the equity line through Dec. 31, 2028.
-
The pricing period was shortened. An amendment dated Oct. 26 reduced the period used to calculate the share purchase price from three trading days to one trading day.
-
The purchase price is set at 97% of VWAP. A separate amendment, effective Feb. 4, set the price at 97% of the average daily volume-weighted average price during the applicable pricing period. With the later change to a one-day period, the calculation now uses one trading day rather than three.
-
The clinical presentation concerned ongoing trials. Bhowmick was scheduled to discuss interim efficacy data for ENV-105 at the United Scientific Group’s 11th International Conference on Cancer Research & Drug Development. The announcement identifies the topic and presentation date but does not report trial findings.
Plain-English implications
The extension gives Kairos more time to access the equity line, but it does not itself indicate that the company has drawn funds. Any use of the facility would involve issuing shares, creating potential dilution. The revised pricing formula sets the purchase price at a 3% discount to the relevant VWAP, with the measurement now based on a single trading day rather than three.